Literature DB >> 23500610

Pharmacokinetics and the drug-target residence time concept.

Göran Dahl1, Tomas Akerud.   

Abstract

The concept of drug-target residence time has been in focus in recent drug discovery literature. However, few studies consider the combined effect of pharmacokinetics (PK) and binding kinetics (BK) on the duration of effect of a drug. Using a simple model that takes both PK and BK into account, we found that prolongation of binding owing to a long drug-target residence time can only occur when the binding dissociation is slower than the PK elimination. Data for several drugs and/or drug candidates in the literature indicate that the opposite is observed, that is, they have a slower elimination compared with dissociation. These observations greatly reduce the usability of drug-target residence times for estimating the duration of effect of a drug in vivo.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2013        PMID: 23500610     DOI: 10.1016/j.drudis.2013.02.010

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  48 in total

Review 1.  The drug-target residence time model: a 10-year retrospective.

Authors:  Robert A Copeland
Journal:  Nat Rev Drug Discov       Date:  2015-12-18       Impact factor: 84.694

Review 2.  On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.

Authors:  Georges Vauquelin; Isabelle Van Liefde; David C Swinney
Journal:  Br J Pharmacol       Date:  2016-03-15       Impact factor: 8.739

3.  Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen.

Authors:  Eleanor Jing Yi Cheong; Pramod C Nair; Rebecca Wan Yi Neo; Ho Thanh Tu; Fu Lin; Edmund Chiong; Kesavan Esuvaranathan; Hao Fan; Russell Z Szmulewitz; Cody J Peer; William D Figg; Christina Li Lin Chai; John O Miners; Eric Chun Yong Chan
Journal:  J Pharmacol Exp Ther       Date:  2020-06-17       Impact factor: 4.030

4.  Pharmacodynamic Actions of a Long-Acting PTH Analog (LA-PTH) in Thyroparathyroidectomized (TPTX) Rats and Normal Monkeys.

Authors:  Masaru Shimizu; Eri Joyashiki; Hiroshi Noda; Tomoyuki Watanabe; Makoto Okazaki; Miho Nagayasu; Kenji Adachi; Tatsuya Tamura; John T Potts; Thomas J Gardella; Yoshiki Kawabe
Journal:  J Bone Miner Res       Date:  2016-05-23       Impact factor: 6.741

5.  The implications of target saturation for the use of drug-target residence time.

Authors:  Wilhelmus E A de Witte; Meindert Danhof; Piet H van der Graaf; Elizabeth C M de Lange
Journal:  Nat Rev Drug Discov       Date:  2018-12-28       Impact factor: 84.694

Review 6.  Chemical space of Escherichia coli dihydrofolate reductase inhibitors: New approaches for discovering novel drugs for old bugs.

Authors:  Bharath Srinivasan; Sam Tonddast-Navaei; Ambrish Roy; Hongyi Zhou; Jeffrey Skolnick
Journal:  Med Res Rev       Date:  2018-09-07       Impact factor: 12.944

7.  Mechanism of the Association Pathways for a Pair of Fast and Slow Binding Ligands of HIV-1 Protease.

Authors:  Yu-Ming M Huang; Mark Anthony V Raymundo; Wei Chen; Chia-En A Chang
Journal:  Biochemistry       Date:  2017-02-21       Impact factor: 3.162

8.  Kv 11.1 (hERG)-induced cardiotoxicity: a molecular insight from a binding kinetics study of prototypical Kv 11.1 (hERG) inhibitors.

Authors:  Z Yu; A P IJzerman; L H Heitman
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

Review 9.  Biophysics in drug discovery: impact, challenges and opportunities.

Authors:  Jean-Paul Renaud; Chun-Wa Chung; U Helena Danielson; Ursula Egner; Michael Hennig; Roderick E Hubbard; Herbert Nar
Journal:  Nat Rev Drug Discov       Date:  2016-08-12       Impact factor: 84.694

10.  Effects of target binding kinetics on in vivo drug efficacy: koff , kon and rebinding.

Authors:  Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2016-07-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.